drugset / Trial / NCT00783146

Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. vs. Placebo for Treating Seasonal Allergic Rhinitis (SAR) (Study P04054)

NCT00783146

Phase 4 Completed 728 enrolled Organon and Co
RandomizedParallel-groupTriple-blindTreatment

Summary

This was a randomized, double-blind, parallel-group, multicenter study that used both an active control (fexofenadine) and a placebo control to evaluate desloratadine 5 mg once daily during a 15-day treatment period. The active treatments and placebo were allocated in a 2:2:1 ratio.

Timeline

Start
2004-08-01
Primary completion
2004-10-01
Completion
2004-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Desloratadine Small molecule 5 mg Oral
Comparator Fexofenadine Unknown 180 mg Oral